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Articular cartilage defects may result from injury
or osteochondral pathology, such as osteonecro-
sis and osteochondritis dissecans. In adults, these
defects heal poorly and progress to catastrophic
degenerative arthritis. Articular cartilage is a thin
viscoelastic layer, usually less than 3 mm thick,
which covers the articulating surface of the bone
in a diarthrodial joint, and permits a smooth mo-
tion with minimal friction against the opposite
contacting cartilage. Cartilage is constituted by 
a unique extracellular matrix (ECM) produced
and maintained by a limited number of chondro-
cytes, which are distributed predominantly in the
deep layer near the osteochondral junction, and
are trapped by the ECM, with much limited abil-
ity of migration. The ECM has a structural func-
tion, contributes to the mechanical property of
cartilage, has a feedback regulatory role on chon-
drocyte activities,1 and also characterizes the phe-
notype of the chondrocytes. The whole structure
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Articular cartilage defects heal poorly and lead to catastrophic degenerative arthritis. Clinical experience
has indicated that no existing medication substantially promotes the healing process and the cartilage 
defect requires surgical replacement, preferably with an autograft. However, there is a shortage of articular
cartilage that can be donated for autografting. A review of previous unsuccessful experiences reveals the
reason for the current strategy to graft cartilage defects with regenerated cartilage. Autologous cartilage 
regeneration is a cell-based therapy in which autogenous chondrocytes or other chondrogenic cells 
are cultured to constitute cartilaginous tissue according to the principles of tissue engineering. Current
studies are concentrating on improving such techniques from the three elements of tissue engineering,
namely the cells, biomaterial scaffolds, and culture conditions. Some models of articular cartilage regener-
ation have yielded good repair of cartilage defects, in animal models and clinical settings, but the overall
results suggest that there is room for improvement of this technique before its routine clinical application.
Autologous cartilage regeneration remains the mainstay for repairing articular cartilage defects but more
studies are required to optimize the efficacy of regeneration. A more abundant supply of more stable cells,
i.e. capable of maintaining the phenotype of chondrogenesis, has to be identified. Porous scaffolds of 
biocompatible, biodegradable materials that maintain and support the presentation of the chondrogenic
cells need to be fabricated. If the cells are not implanted early to allow their in vivo constitution of cartilage,
a suitable in vitro cultivation method has to be devised for a consistent yield of regenerative cartilage. 
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lacks blood or lymphatic vessels, therefore, the
cell infiltration in the normal inflammation
process after injury is unlikely to occur and in-
jury does not heal.
The clinical finding that articular cartilage
“once destroyed, is not repaired,” has not been
changed since it was first observed by Hunter in
1743.2 Conservative treatment with various medi-
cations gives only temporary relief of symptoms
rather than cure, and clinicians have sought a sur-
gical strategy. Initial surgical interventions aim to
stimulate the natural repair process for rebuilding
cartilage tissue, and include abrasion arthroplasty
to evoke local chondrocytes, and multiple drill-
ing or microfracture to release the subchondral
progenitor cells, which in turn might generate new
cartilage.3,4 The unfavorable outcome of debride-
ment and abrasion chondroplasty has confirmed
the low intrinsic activity of human chondrocytes,
and has led to subsequent serial trials of marrow
stimulation techniques.5 Among the latter, Gridie’s
multiple drilling was first introduced in the 1980s,
but the original idea was the revascularization of
the defect site instead of recruitment of marrow
progenitor cells. The clot cannot remain in the
defect, and only sparse scar tissue can be expected.
Steadman’s microfracture of subchondral bone
may allow more bone marrow to enter the site 
of cartilage defect, where more variety of marrow
content can accumulate. This technique largely
replaced multiple drilling in the 1990s. However,
the reparative tissue is fibrocartilage, which has dif-
ferent biomechanical properties from the native
hyaline cartilage.2
More recent surgical strategies aim to replace
the defect with patches or grafts. Cartilage allo-
graft has problems with preparation and storage,
and chondrocytes expire during the process.6–8 If
implanted freshly, cartilage allograft is challenged
by immune reaction from the immersing synovial
fluid, which was once considered insignificant for
the avascular nature of articular cartilage.9 Auto-
grafting is more promising.10 Mosaicplasty with
autologous osteochondral graft has yielded better
clinical outcomes than other surgical modalities,
including abrasion arthroplasty, Pridie drilling,
and microfracture.11–14 This technique is easily
applied and the grafts self-secure to the subchon-
dral bone without additional fixing procedures
or devices.15 This is a major advantage because
cartilage-only grafts are difficult to fix to the re-
cipient site. Usually, the graft is secured to the
surround native cartilage by sutures, which is a
technically demanding and time-consuming pro-
cedure and may further damage the native tissue.
In addition, the thin patch of graft without a se-
cure osteochondral adhesion may easily detach
from the underlying bone as a result of the shear-
ing force during joint motion. The mosaicplastic
grafts are firmly implanted and can be applied
using a minimally invasive arthroscopic proce-
dure.16 Finally, such osteochondral transplantation
concurrently replaces the pathological subchon-
dral bone that frequently exists with cartilage 
defects, such as those of the osteochondritis dis-
secans and osteonecrosis. Unfortunately, the util-
ity of mosaicplasty has been largely limited by the
extreme shortage of autogenous donor sources
in the human body.
The human body has little spare mature articu-
lar cartilage to serve as autografts, and mosaicplasty
is valid only for smaller-sized cartilage defects.17
Artificially constituted extra cartilage is needed
to repair larger defects. Periosteum or perichon-
drium has been considered a potential tissue to
generate articular cartilage and to patch cartilage
defects.18,19 The progenitor cells residing on the
cambium layer of the periosteum are induced 
by environmental factors at the recipient site to
present as chondrocytes, while the periosteum 
itself serves as a scaffold to accommodate these
cells.20,21 Some success has been reported but 
the results are less favorable than for mosaic-
plasty.18,22,23 Periosteal patching grafts cartilage
defects with progenitor cells rather than mature
chondrocytes, and the mechanism and efficiency
of transformation of progenitor cells to chondro-
genic cells remain unclear. Success is enhanced by
knee motion after transplantation of the perios-
teum,24 but the abrasion force during motion
may cause early suture failure and a subsequent
unsuccessful outcome.
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As with most conventional medicine, all these
historical efforts were clinical observations that
were based on trials and experience, and were
not deduced from evidence-based medicine. The
inadequate basic knowledge about cartilage repair
makes the evolution of these experience-based
techniques difficult and less efficient. Solutions
to the clinical problem of articular cartilage repair
may need multidisciplinary collaboration from
biotechnology.
Nevertheless, these clinical experiences have
led to the development of a new technique that
transplants laboratory-expanded chondrocytes in
an attempt to overcome the inadequate supply
of autogenous cartilage. Autologous chondrocyte
implantation (ACI)25 was first introduced in the
late 1900s. This technique harvests a minimum
amount of autogenous cartilage to retrieve chon-
drocytes, which are cultured in vitro to expand
the population, and seeded onto a biodegrad-
able porous sheet to constitute cartilage. The 
regenerated cartilage is in turn used for grafting.
Although they are not yet being used widely, 
surgical procedures specifically developed using
selected biomaterials have been introduced in
North America and Europe (Carticel; Genzyme
Biosurgery, Cambridge, MA, USA). ACI combines
the concepts of cell therapy and tissue engineering
to regenerate articular cartilage as a patch for the
repair of chondral defects,26,27 and remains the
mainstay of treating articular cartilage defects.
The elements of ACI have been improved contin-
ually to regenerate cartilage of better quality. The
next section reviews the recent progress of such
cartilage regeneration.
Articular Cartilage Regeneration
Articular cartilage regeneration develops new car-
tilage as an autograft to overcome the shortage 
of donor material. In principle, chondrocytes or
chondrogenic cells, with or without preceding
culture to multiply their number, are implanted
into the cartilage defect, where these cells deposit
ECM to constitute cartilage repair. This cell-based
technology has evolved over generations to im-
prove the efficiency of tissue regeneration and
surgical outcome (Table 1).15,28–32 The mainstay of
current practice is known as the third generation,
in which the three elements of tissue engineering
are applied, namely the cells, the scaffold that bears
these cells, and a suitable cultivation environment
(Figure 1). Currently, a fourth generation technique
is on the horizon, with the introduction of stem
cells and various growth factors, but the princi-
ples of tissue engineering remain fundamental to
cartilage regeneration. In general, autologous chon-
drogenic cells are inserted onto a biodegradable
scaffold that supports their growth and chondro-
genesis. The cell-laden scaffold is cultivated with
environmental factors appropriate for enhancing
cell presentation. Adopting the concept of tissue
engineering to cartilage regeneration has made the
related research more systematic and evidence-
based, and by using control studies. Recent evo-
lution of the cartilage regeneration technique can
be categorized by the three above elements of tissue
engineering, and we review the modern modifi-
cations in the following discussion (Table 2).
When constituting a regenerated cartilage, two
strategies have been proposed: (1) in vitro consti-
tution of complete chondral or osteochondral
grafts ready for implantation; and (2) cell-based
repair for in vivo development of regenerated carti-
lage. Although the former seems more straight-
forward, the optimal environmental parameters for
the constitution of cartilaginous tissue have not
yet been defined. Modern designs of bioreactors
may largely improve the yield of such laboratory
work, but the biological and mechanical properties
of the regenerated cartilage are currently inferior
for clinical application. The second strategy re-
gards the intra-articular environment as a naturally
suitable condition for the cultivation of regenerated
cartilage. Instead of well-constituted tissue, cells
are implanted to repair the cartilage defect. This is
similar to other models of cell therapy in current
clinical practice, in which chondrogenic cells
work in vivo to produce cartilaginous substances
and repair chondral defects.33 With this strategy,
we need to: (1) provide a sufficient number of
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chondrogenic cells, which can properly produce
ECM and constitute the regenerated cartilage; and
(2) ensure that these cells remain in the grafted
cartilage defect, for the obvious reason that their
production can accumulate locally. ACI is a typical
example of a technique that uses this strategy.
The original attempt at ACI was a combination
of the two strategies: the chondrocytes were ex-
panded in vitro to reach a sufficient number and
were implanted as cells before constitution of the
tissue. The recently modified ACI processes are
closer to the second strategy.
Chondrogenic cells
Cartilage is relatively a hypocellular tissue, which
contains approximately 100 × 106 cells/cm3 on av-
erage, throughout the full thickness of mature
cartilage. These cells display a unique palisade ar-
chitectural pattern with round, single or columnar
cells within lacunae. Absence of this character is
indicative of degenerative changes or less differ-
entiation.33,34 Properly presenting chondrocytes
produce and organize the ECM that is composed
of type II collagen and glycosaminoglycans.
The limited number of autologous chondro-
cytes from spare cartilage may hardly be adequate
for the high demand of cells to constitute engi-
neered cartilage. The seeding density on bioma-
terials to develop cartilage has been reported as
10–130 × 106 cells/cm3, and is optimized at 60 ×
106 for the best mechanical properties of the
yielded tissue.34–38 To collect adequate cells for
such density, the number of harvested chondro-
cytes has to expand in vitro before seeding. Chon-
drocytes expanded in monolayer culture easily
lose their phenotype and transform to more 
fibroblast-like cells, which possess type I instead
of type II collagen.39 This problem has been im-
proved by recently renovated culture methods; for
example, chondrocytes cultured in type I collagen
gel may preserve their phenotype, and those that
have dedifferentiated may redifferentiate.40
Chondrogenic cells that are in more abundant
supply can be used for cartilage tissue engineering.
Bone-marrow-derived mesenchymal stem cells
(MSCs) are more plentiful, and can be induced
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to form chondrogenic cells in chemically specified
culture media supplemented with transforming
growth factor-β (TGF-β).41,42 These multipotential
cells can also be induced to form osteogenic cells
under different culture conditions, and both types
of induction together may constitute a biphasic
osteochondral construct graft from a single cell
source. Some culture systems add mechanical con-
ditions to enhance the production of cartilaginous
tissue by MSCs.43 MSCs can also be collected from
other origins, including the periosteum, perichon-
drium, adipose tissue, placenta, and fetal tissues.
However, the bone marrow-derived MSCs exhibit
better chondrogenesis than MSCs of other origin,
under presently defined culture and induction
conditions.44
Aging of the cells is an issue when these auto-
genous cell-based techniques are applied to aged
people. Old chondrocytes have much lower ability
to build cartilage than young ones.45 For cartilage
repair in aged people, using cell type with greater
potential, such as bone marrow stromal progenitor
cells, may be more promising.42
The behavior of chondrogenic cells is affected
in many ways, such as: (1) the conditions under
which they are incubated, primarily the substance
that contains the cells; and (2) the physical, chem-
ical and biological factors applied to the cells. These
variables affect the cells’ ability to survive, multi-
ply, present the proper chondrogenic phenotype,
and constitute the cartilage tissue. The influence
of various chemicals, pharmaceutical preparations,
and biological factors on the cells has been inves-
tigated extensively in recent laboratory studies.46
However, reports about the in vivo conditions,
primarily from animal experiments, are relatively
few. There have been even fewer human studies,
which means that cartilage regeneration has a
long way to go before it reaches routine clinical
application.
Biomaterial scaffolds
Biomaterial scaffolds provide the chondrogenic
cells with a temporary habitation, where they sur-
vive, multiply, and produce ECM to constitute re-
generated cartilage. Although the cellular products
are expected to replace the degradable biomaterial,
the process is usually time-consuming and the
scaffold should be implanted before completion
of the process. The biomaterials thus play the role
of a vehicle to transfer cells and therefore should
be compatible with the native tissue around the
recipient site.47
Many natural substances are suitable as the
cell-carrying scaffold for cartilage engineering,
including fibrin, agarose, alginate, collagen, chi-
tosan and hyaluronan. Many of these are hydrogels
and can be designed as injectable in their liquid
form, which blends well with chondrogenic cells.48
After being injected into the recipient site, they
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Cells produce ECM to
constitute tissue:
• Native cells
• Stem cells
• Allogenic cells
Factors to promote
cellular presentation:
• Chemical factors
• Mechanical factors
• Biological factors
 – Growth factors
 – Hormones
Tissue
regeneration
Scaffolds temporarily house cells at
the place of tissue regeneration:
• Degradable biomaterials
• Porous architecture
• Adequate structural strength
Cells
“Seeds”
Biomaterial
scaffolds
“Soil”
Environmental
factors
“Fertilizer”
Figure 1. The “tissue engineering triad”. The cell is the main character to generate tissue. Porous scaffolds made from
absorbable biomaterials provide the habitation for the cells. Cell behavior is directed by the environmental factors. 
The environmental factors are the chemical, physical and biological variables and substances in the culture system.
Repair of articular cartilage defect
J Formos Med Assoc | 2009 • Vol 108 • No 2 93
Ta
b
le
 2
.
A
na
ly
si
s 
of
 s
tr
en
gt
h 
an
d 
w
ea
kn
es
s 
of
 c
ur
re
nt
 in
fo
rm
at
io
n 
on
 c
ar
til
ag
e 
re
ge
ne
ra
tio
n 
by
 th
e 
th
re
e 
el
em
en
ts
 o
f t
is
su
e 
en
gi
ne
er
in
g
El
em
en
ts
St
re
ng
th
W
ea
kn
es
s
A
ut
ho
rs
’ p
re
fe
re
nc
e
Ce
lls
1.
St
em
 c
el
ls
 a
re
 in
du
ce
d 
to
 c
ho
nd
ro
ge
ni
c 
1.
Ch
on
dr
oc
yt
es
 e
xp
an
de
d 
w
ith
 
A
ut
ol
og
ou
s 
ch
on
dr
oc
yt
es
 a
re
 e
ffe
ct
iv
e 
ce
lls
, l
ar
ge
ly
 s
ol
ve
s 
th
e 
do
no
r s
ho
rt
ag
e 
co
nv
en
tio
na
l m
on
ol
ay
er
 c
ul
tu
re
 
an
d 
sa
fe
 fo
r c
ar
til
ag
e 
re
ge
ne
ra
tio
n 
of
 c
ho
nd
ro
cy
te
s.
de
di
ffe
re
nt
ia
te
 e
as
ily
 a
nd
 lo
se
 th
ei
r 
ba
se
d 
on
 c
ur
re
nt
 in
fo
rm
at
io
n.
2.
W
ith
 im
pr
ov
ed
 h
an
dl
in
g 
of
 a
llo
ge
ne
ic
 
ch
on
dr
og
en
ic
 p
he
no
ty
pe
.
ch
on
dr
oc
yt
es
, t
he
se
 c
el
ls
 c
an
 b
e 
an
 
2.
In
du
ct
io
n 
of
 s
te
m
 c
el
ls
 re
qu
ire
s 
al
te
ra
tiv
e 
ce
ll 
so
ur
ce
 fo
r c
ar
til
ag
e 
ch
em
ic
al
ly
 d
ef
in
ed
 c
ul
tu
re
 m
ed
iu
m
 
re
ge
ne
ra
tio
n.
su
pp
le
m
en
te
d 
w
ith
 s
pe
ci
fic
 g
ro
w
th
 
fa
ct
or
s,
 w
hi
ch
 m
ay
 re
su
lt 
in
 
si
de
-e
ffe
ct
s 
in
 h
um
an
 u
se
.
Sc
af
fo
ld
s
1.
M
or
e 
va
rie
tie
s 
of
 s
ca
ffo
ld
s 
ar
e 
de
ve
lo
pe
d,
 
1.
Fe
w
 o
f t
he
se
 b
io
m
at
er
ia
ls
 h
av
e 
Bi
ph
as
ic
 o
st
eo
ch
on
dr
al
 s
ca
ffo
ld
 c
an
 b
e 
w
ith
 v
ar
io
us
 n
ov
el
 b
io
m
at
er
ia
ls
 a
nd
 s
ca
ffo
ld
 
be
en
 p
ro
ve
d 
sa
fe
 in
 h
um
an
 u
se
.
se
cu
re
ly
 im
pl
an
te
d 
w
ith
ou
t a
dd
iti
on
al
 
m
ic
ro
-a
rc
hi
te
ct
ur
e.
2.
Ve
ry
 li
m
ite
d 
cl
in
ic
al
 in
fo
rm
at
io
n 
fix
at
io
n,
 a
nd
 re
pa
ir 
su
bc
ho
nd
ra
l 
2.
So
m
e 
bi
om
at
er
ia
ls
 c
an
 in
du
ce
 s
te
m
 c
el
ls
 
ab
ou
t t
he
se
 n
ew
 d
ev
el
op
m
en
ts
 
pa
th
ol
og
y 
co
nc
om
ita
nt
ly.
se
ed
ed
 o
n 
th
e 
sc
af
fo
ld
 to
 b
ec
om
e 
ch
on
dr
og
en
ic
.
to
 d
at
e.
3.
Co
m
bi
ni
ng
 w
ith
 s
pe
ci
al
ly
 d
es
ig
ne
d 
su
rg
ic
al
 
in
st
ru
m
en
ts
, n
ew
 s
ca
ffo
ld
s 
he
lp
 to
 d
ev
el
op
 
si
ng
le
, l
es
s-
de
m
an
di
ng
 s
ur
gi
ca
l p
ro
ce
du
re
s 
fo
r c
ar
til
ag
e 
re
pa
ir.
Cu
ltu
re
 
1.
N
ew
 c
ul
tu
re
 te
ch
ni
qu
es
 s
uc
h 
as
 th
e 
1.
Th
e 
m
ol
ec
ul
ar
 b
io
lo
gi
ca
l e
ffe
ct
s 
of
1.
M
in
im
iz
in
g 
th
e 
in
 v
itr
o
cu
ltu
re
 p
ro
ce
ss
 
co
nd
iti
on
s
3-
D
 s
ys
te
m
 c
an
 b
et
te
r p
re
se
rv
e 
th
e 
m
os
t g
ro
w
th
 fa
ct
or
s 
ar
e 
un
cl
ea
r. 
Ce
lls
 
ca
n 
re
du
ce
 th
e 
co
st
 a
nd
 c
om
pl
ex
ity
 
ch
on
dr
og
en
ic
 a
bi
lit
y 
of
 c
ho
nd
ro
cy
te
s.
m
ay
 b
e 
af
fe
ct
ed
 in
 u
nc
er
ta
in
 w
ay
s.
of
 c
ar
til
ag
e 
re
ge
ne
ra
tio
n.
2.
Se
ru
m
-f
re
e 
cu
ltu
re
 te
ch
ni
qu
e 
2.
Th
e 
la
bo
ra
to
ry
 fa
ci
lit
ie
s 
ar
e 
ex
tr
em
el
y 
2.
In
 v
iv
o
in
tr
a-
ar
tic
ul
ar
 e
nv
iro
nm
en
t 
ca
n 
el
im
in
at
e 
th
e 
ris
k 
of
 z
oo
no
se
s.
ex
pe
ns
iv
e 
to
 m
ee
t t
he
 c
rit
er
ia
 o
f 
m
ay
 b
e 
op
tim
al
 fo
r t
he
 c
on
st
itu
tio
n 
3.
W
he
n 
st
em
 c
el
ls
 a
re
 u
se
d 
as
 th
e 
G
oo
d 
Ti
ss
ue
 P
ra
ct
ic
e.
of
 c
ar
til
ag
in
ou
s 
tis
su
e 
by
 c
ho
nd
ro
cy
te
s.
ch
on
dr
og
en
ic
 c
el
ls
, v
ar
io
us
 g
ro
w
th
 
fa
ct
or
s 
ha
ve
 b
ee
n 
re
se
ar
ch
ed
 to
 
pr
om
ot
e 
th
e 
ce
llu
la
r t
ra
ns
fo
rm
at
io
n.
set by gelation to fill in any shape and size of car-
tilage defect.
Fibrin is a major component of blood clots. It
can be used to adhere other engineered cartilage
onto the recipient site, as a stand-alone scaffold,
or as a growth factor.49,50 Its utility is much limited
by its inferior mechanical properties, the possi-
bility of evoking immune and inflammatory re-
sponses, and its inability to allow immigration
of host cells. Agarose and alginate have better
mechanical strength than fibrin, and have been
reported to support the regeneration of cartilage
in a rabbit model.51 However, they are not suffi-
ciently strong to survive the friction of joint motion
in larger animals and are not absorbed well by
the body.
Some native components of joint tissues that
are considered to have the best biocompatibility
evoke the least immune response. Collagen sponge
has been used in many studies that have loaded
chondrocytes or MSCs to build cartilage in vitro
or in vivo in various animals.52–56 It has also been
used with other materials and techniques such 
as gene treatment to enhance cartilage regenera-
tion.57,58 However, collagen is only available from
living creatures, which means that it is expensive
and has the possibility of transmitting prion-
induced diseases, especially with collagen of bovine
origin. Furthermore, human cells cultured in con-
tact with such animal-derived protein may express
molecules that induce the host immune response,
which would be harmful for the implanted cells.59
Hyaluronan is a native component of synovial
fluid and ECM of cartilage, and has been used for
cartilage engineering.60–62 Although not a native
substance in the human body, chitosan is a poly-
saccharide and evokes minimal inflammatory 
reaction, at least theoretically. It has been prepared
as a thermally sensitive product that is injectable
as a liquid that sets to gel at body temperature.63
Synthetic polymeric scaffolds also have poten-
tial for tissue engineering, with the advantages of
reliable sources and flexibility by manipulating
the fabrication process. The most widely used are
the poly-α-hydroxy esters, especially polylactic acid
(PLA) and polyglycolic acid. These polymers have
been approved for clinical use in the USA and are
manufactured for routine hospital or surgical use.
They are readily made into scaffolds for tissue en-
gineering, in the form of foam or woven or non-
woven fiber mesh. Products of these polymers
have much better mechanical strength than those
of natural substances, which makes it easier for
them to be fixed to the recipient site, and makes
them more resistant to the friction of joint mo-
tion.64 Copolymers of these two substances allow
adjustment of the degradation rate of the scaffold.
This is important because the residence time of
the implanted polymer must be sufficient to serve
its scaffold purpose, but not so long as to impede
tissue regeneration. If MSCs are seeded onto a PLA
scaffold, they display chondrocyte differentiation
in culture medium supplemented with TGF-β.65
Other polymers of interest include poly(ethylene
glycol)-terephthalate, poly(butylene terephthalate),
poly(ethylene glycol) fumarate, poly(N-isopropy-
lacrylamide), and carbon fiber scaffolds.66–69
Beside the biomaterial content, the design of
the scaffold architecture may also affect the seeded
cells. Because the ECM of natural cartilage distrib-
utes nonhomogeneously, with the chondrocytes
present predominantly near the osteochondral
junction and collagen fibers along the articular
surface, a scaffold architecture that mimics the
natural environment may facilitate the growth of
seeded chondrocytes. A layered agarose scaffold
with such depth-dependent nonhomogeneity has
been designed for good in vitro regeneration of
cartilage from chondrocytes.70
The clinical success of mosaicplasty brings the
idea of engineering biphasic osteochondral com-
posites for cartilage repair.47,71,72 Osteochondral
repair has several advantages over cartilage-only
repair. A uniform, predefined tidemark at the os-
teochondral junction can prevent the detachment
of cartilage from the subchondral bone during
joint motion. The osseous phase of the engineered
osteochondral composite is a rigid support of the
overlying chondral phase, and can self-secure to
the recipient site by press-fit. Many studies use
tricalcium phosphate (TCP), a major component
of bone minerals, to fabricate this osseous phase.
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When the marrow stromal cells at the recipient
site make contact with the TCP content of the
implant, they become osteogenic and build bony
replacement within the scaffold, such that the
implant integrates well with the host bone.73–76
Alternatively, osteogenic and chondrogenic cells
can be preseeded concurrently and respectively
to their corresponding phases. The chondrogenic
cells preferentially stay in the chondral phase of
the construct.71,72
Culture conditions
Chondrocytes or other induced chondrogenic
cells should be able to produce ECM that consti-
tutes the regenerated cartilage. In both of the
aforementioned strategies, chemical, physical and
biological factors may be applied to promote cel-
lular presentation when culturing the construct.
Bioreactors are designed to adjust environmental
factors for the optimal performance of the chon-
drocytes.77,78 Factors of interest include the friction
caused by surface motion, compressive stress,
oxygen tension, hydrostatic force, and dynamic
mechanical stimulation.79–83
MSCs have been considered to substitute for
insufficient autogenous chondrocytes, therefore,
more factors are required to efficiently induce these
cells to become chondrogenic. Various cytokines
and growth factors are added to the chemically
defined culture media to promote chondrogene-
sis, including various isoforms of TGF-β, bone
morphogenic protein (BMP), activin, osteogenic
protein-1, fibroblast growth factor-2 (FGF-2), 
insulin-like growth factor-1 (IGF-1), prolactin, in-
terleukin-1β, Cyr-61, and growth hormone.84–100
The most well known is the superfamily of TGF-β,
which consists of more than 40 polypeptides
that share high homology and affect the cells
through similar transmembranous receptor com-
plexes and intracellular pathways.101,102 The cascade
triggered by TGF-β can cross-talk with the Wnt
pathway.103 Some other nonproteinaceous chem-
ical factors have also been shown to promote
chondrogenesis, including prostaglandin E2, thy-
roxin, 1.25-dihydroxy vitamin D, ascorbic acid,
dexamethasone, ethanol, staurosporine, dibutyryl
cAMP, concanavalin A, and vanadate.104–116 These
chemicals are less labile, with a longer half-life than
the protein-based factors, and are thus advanta-
geous for prolonged in vitro culture over several
weeks.
Regardless of the nature of the cells, standard
culture conditions require the presence of serum,
basically of bovine origin. The risk of undesired
pathogen transmission has been debated when
the cells are implanted to humans. Autologous
serum-supplemented culture medium has become
the state of the art for ACI, but serum-free culture
is more attractive.117 The avascular condition of
natural cartilage does not suggest that serum is
needed to support the chondrocytes. One study
has even indicated that serum hinders the chon-
drogenic ability of chondrocytes.118 Serum-free
culture is worthy of further development to develop
regenerated cartilage for clinical application.
Needs and Perspectives
Safety of engineered cartilage
Either chondrocytes or MSCs are used to constitute
engineered cartilage, and in vitro manipulation
of the cells is necessary in most of the currently
available systems. When the constructed cartilage
tissue is considered for clinical use, the safety of
the whole process has been debated and the cost
is high. The entire process has to be conducted
with expensive laboratory facilities that meet the
high standard of good tissue practice. In addition,
all reagents involved in the process should be
proven as safe for human use. More complicated
manipulation of the cells will arouse more con-
cern that the cells may be affected in unknown
ways. When developing a system to regenerate
cartilage for clinical application, we should always
consider its safety and simplicity, even if it is nec-
essary to compromise the quality of the regenerated
tissue.
Surgical applicability
The ultimate goal of cartilage engineering is the
surgical application of the product in humans.
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Animal experiments have testified to the surgical
applicability and efficiency of cartilage defect re-
pairs, and this is necessary before clinical appli-
cation of the models.119 The in vivo environment
in animal experiments can be a naturally optimized
“bioactive chamber” to construct cartilage tissue
without any artificial bioreactor.26 An ideal animal
model has similar articular anatomy and physi-
ology to those in humans, with suitable dimen-
sions for surgical operation. Porcine and canine
models are good examples in the literature for
cartilage repair.
A well-designed model of cartilage repair
should be easily applicable in the operating room,
so that the operative time is shortened and surgical
invasion minimized. For example, the biphasic
osteochondral construct can self-secure to the
prepared recipient site within seconds. We have
previously developed a system that implants
freshly harvested chondrocytes directly to the
cartilage defect, using a specially designed biphasic
biodegradable scaffold.76,120 The cylindrical scaf-
fold is a porous construction with two phases: 
a thin, spongy chondral phase of PLA on the top,
and a more rigid osseous phase of PLA–TCP as
the base (Figure 2). With a low seeding density
of 2×106 chondrocytes/cm3 to the chondral phase,
the subsequent in vivo growth yields good cartilage
tissue at the grafted site in porcine knees (Figure 3).
This avoids the complex culture process and fin-
ishes the harvest of autogenous chondrocytes and
their implantation in one surgical procedure.
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Figure 3. Demonstration of osteochondral repair with a biphasic scaffold in a porcine model. Autogenous cartilage was
harvested, pulverized, and enzymatically treated to retrieve chondrocytes, which were then seeded onto the chondral
phase of the scaffold. (A) An osteochondral defect of the identical dimension to the prepared scaffold was created artifi-
cially on the femoral condyle in the knee joint. The prepared scaffold was press-fit installed. (B) Six months after surgery,
the defect was repaired with regenerated cartilage. (C) Microsection of the recipient site shows the histology of the 
regenerated tissue (hematoxylin & eosin, 1×). Without preseeding cells to the osseous phase, the bone marrow stromal
cells migrated into the porous scaffold and mineralized the space. The regenerated tissue, both chondral and osseous, 
integrated well with the surrounding native tissue.
Figure 2. The cylindrical biphasic osteochondral scaffold.
The diameter and height of this cylinder are 8 mm.
From laboratory to clinic
As a result of the unfavorable clinical experiences of
cartilage repair in the past, biotechnology has been
introduced to this field for evidence-based devel-
opment of a solution. The knowledge to date sup-
ports that articular cartilage is best repaired with
autologous engineered cartilage, and a lot of re-
search has been carried out to improve cartilage
regeneration. Although the efficacy of regeneration
has much improved in the laboratory and animal
studies, most findings have not been investigated
for their clinical safety and performance. Further
studies should highlight their clinical relevance to
facilitate the development of products applicable
to humans.
We need to organize currently available knowl-
edge to develop clinically applicable models of
cartilage repair, on the basis of autogenous chon-
drogenic cell implantation. A clinically applicable
model of cartilage regeneration should be safe, effi-
cient, and as simple as possible. Our model de-
scribed in the previous section may be an example.
It can be finished in a single seed-and-implant sur-
gery procedure, which decreases the surgical risks
and complications from repetitive operations of
conventional ACI. If the site of repair allows an
arthroscopic approach, the surgery can be done in
a minimally invasive manner within a short time,
estimated at 1 hour. By avoiding the complex treat-
ment of the autogenous cells in vitro, the safety 
of the procedure can be improved and the cost
reduced.
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